A
Aerpio Therapeutics
Biotechnology company, develops new small molecules and monoclonal antibodies for the treatment of vascular diseases
About Aerpio Therapeutics
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for eye diseases and other vascular-related conditions. The company operates primarily in the healthcare and pharmaceutical markets, targeting conditions such as glaucoma, diabetic nephropathy, and diabetic retinopathy. Aerpio's main clients include healthcare providers, hospitals, and clinics that treat patients with these conditions.
The company’s business model revolves around the research and development (R&D) of novel therapeutics. Aerpio leverages its proprietary technology, particularly the Tie2 pathway, which plays a crucial role in maintaining vascular stability. By activating this pathway, Aerpio aims to develop drugs that can effectively treat diseases caused by vascular dysfunction.
Aerpio's pipeline includes several promising drug candidates. Razuprotafib (AKB-9778) is being tested for its effectiveness in treating open-angle glaucoma and diabetic nephropathy. Another candidate, ARP-1536, is aimed at treating diabetic retinopathy. Additionally, Aerpio is exploring treatments for inflammatory bowel disease (IBD) and certain types of cancer.
The company generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales if the drugs are successfully brought to market. Aerpio also benefits from grants and funding from various health organizations to support its R&D activities.
In summary, Aerpio Pharmaceuticals is a specialized player in the biopharmaceutical sector, focusing on innovative treatments for eye diseases and vascular-related conditions. The company’s revenue model is heavily reliant on strategic partnerships and successful drug development.
Source: Dealroom company dataNews
Open roles
Aerpio Therapeutics in the Cincinnati ecosystem
The Aerpio Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Venture Investors Health Fund
Athenian Venture Partners- KPKearny Venture Partners
Novartis Venture Fund- TPTriathlon Medical Venture Partners
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aerpio Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aerpio Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.



